Likely only safety as the first steps of any dose escalation study are usually below the therapeutically effective dose. The answer also depends on what dose level ethics lets us start at.
I would also add that RC220 going into humans via a peripheral vein with no problems would be a major piece of valuable clinical data.
Likely only safety as the first steps of any dose escalation...
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.73 |
Change
-0.110(5.98%) |
Mkt cap ! $294.6M | |||
| Open | High | Low | Value | Volume |
| $1.88 | $1.89 | $1.71 | $403.7K | 228.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 5808 | $1.71 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.73 | 3094 | 1 |
View Market Depth
| Last trade - 15.44pm 24/06/2024 (20 minute delay) ? |
| RAC (ASX) Chart |